NASDAQ : NAGE
Niagen Bioscience, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.5 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 198.23M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 184.75M |
| Enterprise Value | 120.49M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 79.29M |
| Shares Outstanding | 79.29M |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | -2.44% |
| Owned by Insiders (%) | 25.02% |
| Owned by Institutions (%) | 45.29% |
| Float | 59.07M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 12.25 |
| Forward PE | 39.83 |
| PS Ratio | 1.43 |
| Forward PS | 1.29 |
| PB Ratio | 2.23 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | 32.56 |
| P/OCF Ratio | 31.06 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 7.54 |
| EV / Sales | 0.93 |
| EV / EBITDA | 12.56 |
| EV / EBIT | 13.99 |
| EV / FCF | 21.24 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.50 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | 0.41 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 21.80% |
| Return on Assets (ROA) | 5.44% |
| Return on Invested Capital (ROIC) | 44.00% |
| Return on Capital Employed (ROCE) | 9.41% |
| Weighted Average Cost of Capital (WACC) | 15.15% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $136,675 |
| Employee Count | 117 |
| Asset Turnover | 1.30 |
| Inventory Turnover | 2.63 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.04M |
| Effective Tax Rate | 6.09% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.02 |
| 52-Week Price Change | -67.95% |
| 50-Day Moving Average | 2.86 |
| 200-Day Moving Average | 3.92 |
| Relative Strength Index (RSI) | 30.26 |
| Average Volume (20 Days) | 495,807 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.18M |
| Short Previous Month | 3.87M |
| Short % of Shares Out | 5.27% |
| Short % of Float | 7.07% |
| Short Ratio (days to cover) | 7.73 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 129.08M |
| Gross Profit | 82.92M |
| Operating Income | 8.62M |
| Pretax Income | 17.03M |
| Net Income | 15.99M |
| EBITDA | 9.59M |
| EBIT | 8.62M |
| Earnings Per Share (EPS) | $0.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 66.59M |
| Total Debt | 2.33M |
| Net Cash | 64.26M |
| Net Cash Per Share | $0.81 |
| Equity (Book Value) | 82.53M |
| Book Value Per Share | 1.04 |
| Working Capital | 82.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 5.95M |
| Capital Expenditures | -275,000 |
| Depreciation & Amortization | 976,000 |
| Net Borrowing | -6,000 |
| Free Cash Flow | 5.67M |
| FCF Per Share | $0.07 |
Margins
| Measure | Value |
|---|
| Gross Margin | 64.24% |
| Operating Margin | 6.67% |
| Pretax Margin | 13.19% |
| Profit Margin | 12.39% |
| EBITDA Margin | 7.43% |
| EBIT Margin | 6.67% |
| FCF Margin | 4.40% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | 8.16% |
| FCF Yield | 3.07% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.92 |
| Price Target Difference | 411.59% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 9.94% |
| EPS Growth Forecast (3Y) | -28.97% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 13, 2016 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.6 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |